Health Committee to vote on von Eschenbach
Executive Summary
Senate Health Committee is scheduled to vote Sept. 20 on the nomination of Andrew von Eschenbach to be permanent commissioner of FDA, despite the prospect of future holds. Sen. David Vitter (R-La.) has threatened a hold to push for a drug importation program, while Sen. Jim DeMint (R-S.C.) may use a hold to protest the continued marketing of Danco Laboratories' abortifacient Mifeprex. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) recently released a hold on von Eschenbach following FDA's approval of the morning-after pill Plan B for OTC use (1"The Pink Sheet" Aug. 28, 2006, p. 9)...
You may also be interested in...
Plan B Approval Clears The Way For Von Eschenbach Confirmation
FDA's decision to approve the emergency contraceptive Plan B for over-the-counter sale to women age 18 and older opens the door to a vote on FDA Acting Commissioner Andrew von Eschenbach's nomination to the permanent post
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.